S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Prescription Drug User Fee Reauthorization issues; S. 959 Pharmaceutical Compounding Quality and Accountability Act; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R. 2186, Verifying Authority and Legality In Drug Compounding Act of 2013.
S. 214, Preserve Access to Affordable Generics; Implementation of P.L. 111-148, Patient Protection & Affordable Care Act; Prescription Drug User Fee Reauthorization issues; S. 959 Pharmaceutical Compounding Quality and Accountability Act; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R. 2186, Verifying Authority and Legality In Drug Compounding Act of 2013.
General budget and appropriations issues.
Duration: March 1, 2010
to
June 30, 2014
General Issues: Health Issues , Pharmacy , Budget/Appropriations
Spending: about $2,970,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2010: U.S. Senate, House of Representatives
Affiliated organizations: Ranbaxy Labs Ltd
Related Foreign Entities:
Ranbaxy Labs Ltd (Gurgaon, IND); contribution to lobbying: $90000; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2014
Squire Patton Boggs (formerly Patton Boggs LLP) terminated an engagement in which they represented Ranbaxy Inc. on July 9, 2014.
Original Filing: 300654471.xml
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Prescription Drug User Fee Reauthorization issues; S. 959 Pharmaceutical Compounding Quality and Accountability Act; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R. 2186, Verifying Authority and Legality In Drug Compounding Act of 2013.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 214, Preserve Access to Affordable Generics; Implementation of P.L. 111-148, Patient Protection & Affordable Care Act; Prescription Drug User Fee Reauthorization issues; S. 959 Pharmaceutical Compounding Quality and Accountability Act; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R. 2186, Verifying Authority and Legality In Drug Compounding Act of 2013.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General budget and appropriations issues.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $180,000. The report was filed on April 20, 2014.
Original Filing: 300643054.xml
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Prescription Drug User Fee Reauthorization issues; S. 959 Pharmaceutical Compounding Quality and Accountability Act; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R. 2186, Verifying Authority and Legality In Drug Compounding Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 214, Preserve Access to Affordable Generics; Implementation of P.L. 111-148, Patient Protection & Affordable Care Act; Prescription Drug User Fee Reauthorization issues; S. 959 Pharmaceutical Compounding Quality and Accountability Act; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R. 2186, Verifying Authority and Legality In Drug Compounding Act of 2013.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $180,000. The report was filed on Jan. 18, 2014.
Original Filing: 300620072.xml
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Prescription Drug User Fee Reauthorization issues; S. 959 Pharmaceutical Compounding Quality and Accountability Act; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R. 2186, Verifying Authority and Legality In Drug Compounding Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 214, Preserve Access to Affordable Generics; Implementation of P.L. 111-148, Patient Protection & Affordable Care Act; Prescription Drug User Fee Reauthorization issues; S. 959 Pharmaceutical Compounding Quality and Accountability Act; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R. 2186, Verifying Authority and Legality In Drug Compounding Act of 2013.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $180,000. The report was filed on Oct. 19, 2013.
Original Filing: 300600843.xml
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Prescription Drug User Fee Reauthorization issues; S. 959 Pharmaceutical Compounding Quality and Accountability Act; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R. 2186, Verifying Authority and Legality In Drug Compounding Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 214, Preserve Access to Affordable Generics; Implementation of P.L. 111-148, Patient Protection & Affordable Care Act; Prescription Drug User Fee Reauthorization issues; S. 959 Pharmaceutical Compounding Quality and Accountability Act; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R. 2186, Verifying Authority and Legality In Drug Compounding Act of 2013.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $180,000. The report was filed on July 21, 2013.
Original Filing: 300580667.xml
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Prescription Drug User Fee Reauthorization issues; S. 959 Pharmaceutical Compounding Quality and Accountability Act; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R. 2186, Verifying Authority and Legality In Drug Compounding Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 214, Preserve Access to Affordable Generics; Implementation of P.L. 111-148, Patient Protection & Affordable Care Act; Prescription Drug User Fee Reauthorization issues; S. 959 Pharmaceutical Compounding Quality and Accountability Act; S. 957, Drug Supply Chain Security Act; H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R. 2186, Verifying Authority and Legality In Drug Compounding Act of 2013.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $180,000. The report was filed on April 21, 2013.
Original Filing: 300558498.xml
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Prescription Drug User Fee Reauthorization issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 214, Preserve Access to Affordable Generics; Implementation of P.L. 111-148, Patient Protection & Affordable Care Act; Prescription Drug User Fee Reauthorization issues; H.R. 8, the American Taxpayer Relief Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $180,000. The report was filed on Jan. 20, 2013.
Original Filing: 300536273.xml
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Prescription Drug User Fee Reauthorization issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 27, Preserve Access to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care Act; Prescription Drug User Fee Reauthorization issues; H.R. 8, the American Taxpayer Relief Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $180,000. The report was filed on Oct. 21, 2012.
Original Filing: 300515930.xml
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Prescription Drug User Fee Reauthorization issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 27, Preserve Access to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care Act; Prescription Drug User Fee Reauthorization issues.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $180,000. The report was filed on July 17, 2012.
Original Filing: 300487334.xml
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Prescription Drug User Fee Reauthorization issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 27, Preserve Access to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care Act; Prescription Drug User Fee Reauthorization issues.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $180,000. The report was filed on April 18, 2012.
Original Filing: 300462905.xml
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; H.R. 3630, the Middle Class Tax Relief Job Creation Act; Prescription Drug User Fee Reauthorization issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 27, Preserve Access to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care Act; H.R. 3630, the Middle Class Tax Relief and Job Creation Act; Prescription Drug User Fee Reauthorization issues.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $180,000. The report was filed on Jan. 17, 2012.
Original Filing: 300438294.xml
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; S. 23/H.R. 1249 the America Invents Act; H.R. 2112, Agriculture, Rural Development, Food & Drug Administration, and Related Agencies Appropriations Act of 2012; H.R. 2055, the Consolidated Apppropriations Act of 2012; H.R. 3765, the Temporary Payroll Tax Cut Contribution Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $180,000. The report was filed on Oct. 20, 2011.
Original Filing: 300426592.xml
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Budget Control Act of 2011 (P.L. 112-25); Budget S. 23/H.R. 1249, the America Invents Act; H.R. 1, Full Year Continuing Appropriations Act; H.R. 2112, Agriculture, Rural Development, Food & Drug Administration, and Related Agencies Appropriations Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Budget Control Act of 2011 (P.L. 112-25); S. 23/H.R. 1249 the America Invents Act; H.R. 1, Full Year Continuing Appropriations Act; H.R. 2112, Agriculture, Rural Development, Food & Drug Administration, and Related Agencies Appropriations Act of 2012.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $180,000. The report was filed on July 18, 2011.
Original Filing: 300392158.xml
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Implementation of P.L. 111-152, Health Care & Education Reconciliation; S. 23/H.R. 1249, the America Invents Act; H.R. 1, Full Year Continuing Appropriations Act; H.R. 2112, Agriculture, Rural Development, Food & Drug Administration, and Related Agencies Appropriations Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Implementation of P.L. 111-152, Health Care & Education Reconciliation; S. 23/H.R. 1249 the America Invents Act; H.R. 1, Full Year Continuing Appropriations Act; H.R. 2112, Agriculture, Rural Development, Food & Drug Administration, and Related Agencies Appropriations Act of 2012.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $160,000. The report was filed on April 19, 2011.
Original Filing: 300369191.xml
Lobbying Issues
S.27, Preserve Acess to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Implementation of P.L. 111-152, Health Care & Education Reconciliation; H.R. 4, Comprehensive 1099 Taxpayer Protection and Repaymentof Exchange Subsidy Overpayments Act; S. 23, the America Invents Act; H.R. 1, Full Year Continuing Appropriations Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $180,000. The report was filed on Jan. 20, 2011.
Original Filing: 300351955.xml
Lobbying Issues
S.369/HR 1706, Preserve Acess to Affordable Generics; HR 759, FDA Globalization Act; S.3690, Drug Safety & Accountability Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care; Implementation of P.L. 111-152, Health Care & Education Reconciliation; S.3677, the Financial Services & General Government Appropriations Act; HR3082, Continuing Appropriations & Surface Transportation Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $160,000. The report was filed on Oct. 20, 2010.
Original Filing: 300324193.xml
Lobbying Issues
S. 369/H.R. 1706, Preserve Access to Affordable Generics; H.R. 759, FDA Globalization Act; S. 3690, Drug Safety and Accountability Act; Implementation of P.L. 111-148, Patient Protection and Affordable Care; Implementation of P.L. 111-152, Health Care and Education Reconciliation
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $160,000. The report was filed on July 22, 2010.
Original Filing: 300304715.xml
Lobbying Issues
P.L. 111-148, Patient Protection and Affordable Care;
P.L. 111-152, Health Care and Education Reconciliation;
H.R. 3200, America's Affordable Health Choices;
S. 1796, America's Healthy Futures;
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 369, Preserve Access to Affordable Generics; H.R. 759, FDA Globalization
Agencies Lobbied
U.S. Senate
1st Quarter, 2010
In Q1, PATTON BOGGS LLP lobbied for Ranbaxy Inc. , earning $30,000. The report was filed on July 22, 2010.
Original Filing: 300304657.xml
Lobbying Issues
P.L. 111-148, Patient Protection and Affordable Care;
P.L. 111-152, Health Care and Education Reconciliation;
H.R. 3200, America's Affordable Health Choices;
S. 1796, America's Healthy Futures;
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 369, Preserve Access to Affordable Generics; H.R. 759, FDA Globalization
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
Patton Boggs LLP filed a lobbying registration on July 19, 2010 to represent Ranbaxy Inc., effective March 1, 2010.
Original Filing: 300300422.xml
Issue(s) they said they’d lobby about: PL 111-148, Patient Protect & Affordable Care; PL 111-152, Health Care &Educ Reconcil'n; H.R. 3200, Amer's Affordable Health Choices; S 1796, America's Healthy Futures; S 369, Preserve Access to Affordable Generics; HR 759, FDA Global'n .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...